ES2167356T3 - Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel. - Google Patents

Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.

Info

Publication number
ES2167356T3
ES2167356T3 ES94902447T ES94902447T ES2167356T3 ES 2167356 T3 ES2167356 T3 ES 2167356T3 ES 94902447 T ES94902447 T ES 94902447T ES 94902447 T ES94902447 T ES 94902447T ES 2167356 T3 ES2167356 T3 ES 2167356T3
Authority
ES
Spain
Prior art keywords
thiourethylens
thiabendazol
autoimmunity
skin diseases
inflammatory skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902447T
Other languages
English (en)
Inventor
Alan N Elias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2167356T3 publication Critical patent/ES2167356T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION PROPORCIONA NUEVOS USOS DE FARMACOS DE LA CLASE DEL TIOUREILENO Y TIABENDAZOLES. ESTOS NUEVOS USOS INCLUYEN METODOS DE TRATAMIENTO PARA UNA VARIEDAD DE CONDICIONES Y ENFERMEDADES, INCLUYENDO LA SORIASIS, OTRAS DERMATOSIS ATOPICAS Y CONDICIONES INFLAMATORIAS QUE TIENEN UNA BASE AUTOINMUNE, ASI COMO OTRAS ENFERMEDADES AUTOINMUNES, INCLUYENDO ENFERMEDADES REUMATICAS, Y RECHAZO DE TRANSPLANTE.
ES94902447T 1992-11-30 1993-11-30 Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel. Expired - Lifetime ES2167356T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/982,702 US5310742A (en) 1992-11-30 1992-11-30 Uses for thioureylenes
PCT/US1993/011537 WO1994012183A1 (en) 1992-11-30 1993-11-30 Use of thioureleylenes and thiabendazole in autoimmune diseases

Publications (1)

Publication Number Publication Date
ES2167356T3 true ES2167356T3 (es) 2002-05-16

Family

ID=25529427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902447T Expired - Lifetime ES2167356T3 (es) 1992-11-30 1993-11-30 Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.

Country Status (6)

Country Link
US (1) US5310742A (es)
EP (1) EP0670723B1 (es)
AU (1) AU5681694A (es)
DE (1) DE69331105T2 (es)
ES (1) ES2167356T3 (es)
WO (1) WO1994012183A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164641A1 (en) * 1993-06-07 1994-12-22 Dinah S. Singer Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
US6365616B1 (en) 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
CA2345642A1 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
ATE303159T1 (de) * 1998-10-02 2005-09-15 Celtrix Pharma Null igf zur krebsbehandlung
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
AU2003299560A1 (en) * 2002-11-13 2004-06-03 Sepracor, Inc. Compositions and methods for treating or preventing hearing impairment
AU2005282789A1 (en) * 2004-09-01 2006-03-16 Trustees Of Boston University Use of thyroid hormone conversion inhibitors
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
GB2527555B (en) 2014-06-25 2018-09-19 Norbrook Lab Ltd Stable methimazole liquid compositions
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CA3050001A1 (en) * 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4608341A (en) * 1983-05-31 1986-08-26 Interthyr Research Foundation, Inc. Living, fast-growing thyroid cell strain, FRTL-5
US4609622A (en) * 1983-05-31 1986-09-02 Interthyr Research Foundation Inc. Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4853227A (en) * 1987-10-23 1989-08-01 Ciba-Geigy Corporation Transdermal administration of a systemic active agent to a premature neonatal infant
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5087441A (en) * 1989-12-22 1992-02-11 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole
US5010092A (en) * 1989-12-22 1991-04-23 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole

Also Published As

Publication number Publication date
DE69331105T2 (de) 2002-07-11
DE69331105D1 (de) 2001-12-13
EP0670723A1 (en) 1995-09-13
EP0670723B1 (en) 2001-11-07
AU5681694A (en) 1994-06-22
US5310742A (en) 1994-05-10
WO1994012183A1 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
ES2167356T3 (es) Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.
GT199800021A (es) Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
ES2157601T3 (es) Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple.
SV2002000289A (es) Antagonistas del factor liberador de la corticotropina ref. pc10759/20117/bb
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2171971T3 (es) Producto limpiador y de tratamiento con almidon.
ES2156150T3 (es) Combinacion terapeutica que contiene interferon.
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
ES2170771T3 (es) Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
GT199700115A (es) Agentes nicotinicos en terapia.
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
ES2176322T3 (es) Nuevos peptidos opioides para el tratamiento de dolores y su utilizacion.
ES2177636T3 (es) Utilizacion del agua empobrecida en deuterio en la preparacion de cosmeticos.
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
ATE259237T1 (de) Verwendung von isoosmotischen salzlösungen zur verhütung von entzündungen
ES2093582T1 (es) Composicion y procedimiento para el moldeado permanente del cabello.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
ES2174337T3 (es) Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas